The page is the record's research on the issuer — no analyst, no rating, no view. # ImmunityBio, Inc. (NASDAQ: IBRX) — research page As of 2026-11-08 · us-cm-kg · record version 1 ## Identity and listing The issuer is ImmunityBio, Inc., listed on NASDAQ under ticker IBRX, with ISIN US45256X1037 and LEI 529900J9XLBR4HFL4B83. Its security type is Corporate and its sector is 2836 Biological Products, (No Diagnostic Substances). Its jurisdiction is United States, Delaware, and its segment is not on the record. Its listing status is listed, not halted. ## The disclosure read The record holds 69 filings across 41 filing days in the window 2025-11-08 to 2026-11-08. By type, the record holds 31 directors' dealings, 15 regulatory filings, 10 corporate news, 8 results, 3 AGM/EGM, 1 director change and 1 prospectus. The median gap between filing days is 4.0 days. The latest filing is dated 2026-10-14 and is of type corporate_news, and 25 days separate it from the record date. The exchange median is 52 filings, a cadence gap of 6.0 days and a latency of 5.0 days across 4,359 issuers. The sector median is 65.5 filings, a cadence gap of 5.5 days and a latency of 4.0 days across 176 issuers. ## Auditor The auditor is not on the record. The latest annual report cover carries no dei:AuditorName tag, and the location is not on the record. The record holds no auditor changes. ## Events and halts The record holds no listing, delisting or name change lines. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag is listed, not halted. ## Orderability The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04. ## Coverage No research houses were found on the issuer's investor-relations page. ## Open research No openly published research notes were found on the record. ## Licensed Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded. ## As-of depth The issuer's sealed years are 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12. ## Sources 8 source pages are named on this page; every value above carries its own source page and read date in the numbers. - https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange) - https://mapping.gleif.org/api/v2/isin-lei/latest (identity.isin) - https://data.sec.gov/submissions/CIK0001326110.json (identity.jurisdiction) - https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei) - https://mcp.us-cm-kg.ai/events/NASDAQ/IBRX (the disclosure lines) - https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag) - https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter) - https://mcp.us-cm-kg.ai/record/NASDAQ/IBRX (the record) --- Allooloo Technologies Corp. · https://getresearch.ai/us/NASDAQ/IBRX · public-record only · the same page signed and receipted: get_research at https://mcp.getresearch.ai/mcp